A trial looking at celecoxib with standard treatment for certain types of cancer that have spread (LION Trial)
Cancer type:
Status:
Phase:
This trial is looking at adding a drug called celecoxib to to improve treatment for
. This is cancer that has spread into surrounding tissues or to another part of the body.
It is for people who are having their first treatment for advanced:
- triple negative breast cancer
- non small cell lung cancer
- renal cell cancer
More about this trial
You might have as the first treatment for the following types of cancer that have spread:
Immunotherapy helps the to find and kill cancer cells. In some people, it doesn’t work as well as doctors had hoped. So researchers are looking at ways to improve treatment. In this trial they are looking at a drug called celecoxib. It is a
.
Inflammation can make cancers grow. This is because it can cause an enzyme called COX-2 to increase. We know from research that cancer cells with high levels of COX-2 grow more and are better at avoiding the body’s immune system. We also know from early research that anti inflammatory drugs might help immunotherapy to work better.
Celecoxib works by blocking COX-2. Celecoxib is already used to treat inflammatory conditions, like arthritis. It isn’t used currently in the treatment of cancer.
In this trial, everyone has celecoxib. You also have the standard treatment for your cancer type:
- atezolizumab immunotherapy and nab-paclitaxel chemotherapy for triple negative breast cancer
- pembrolizumab immunotherapy for non small cell lung cancer
- ipilimumab and nivolumab immunotherapy for renal cell cancer
The main aims of the trial are to find out:
- how well adding celecoxib to standard treatment works
- more about the side effects
Who can enter
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following main entry conditions apply. You:
- have cancer that has spread into surrounding tissues or to other parts of the body
- have at least one area of cancer that hasn’t been treated with radiotherapy that your doctor can measure on a scan
- have satisfactory blood test results
- have a sample of tissue that was taken within 3 months of joining the trial
- are suitable to have a type of immunotherapy called an immune checkpoint inhibitor
- are fit and active but might not be able to do heavy physical work (performance status 0 or 1)
- are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant
- are at least 18 years old
Triple negative breast cancer group
As well as the main entry conditions above, the following must also apply for this group. You:
- have triple negative breast cancer confirmed with a recent tissue sample
- have the protein PD-L1 on the breast cancer cells
- can’t have surgery to remove the cancer
Non small cell lung cancer group
As well as the main entry conditions above, the following must also apply for this group. You:
- have NSCLC recently confirmed with a tissue or fluid sample
- have the protein PD-L1 in more than half of the lung cancer cells. Your doctor will know this.
- have no evidence of the EGFR gene change (
mutation ), the ALK gene change or the ROS1 gene change in your cancer cells. Your doctor will check this.
- may have previously had chemotherapy for cancer that hadn’t spread. The last dose you had must have been more than 6 months before your cancer got worse.
Renal cell cancer group
As well as the main entry conditions above, the following must also apply for this group. You:
- have clear cell or papillary cell renal cancer
- have medium to high risk renal cell cancer. Your doctor will know this.
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
- have already had treatment for incurable cancer that has spread to surrounding tissues or to other parts of the body
- are having chemotherapy, an experimental treatment or a
targeted cancer drug . You can take part if you are having bisphosphonates or denosumab for cancer spread to the bone.
- have cancer that has spread to the brain or spinal cord and is causing symptoms or your doctor suspects you have this. You can take part if you have had treatment, the cancer is stable and you have stopped taking
steroids. - have cancer that has spread to the tissues that cover the brain and spinal cord
- have had another cancer in the last 5 years. You can take part if you have successfully treated
non melanoma skin cancer ,
in situ cancer of the cervix,
ductal carcinoma of the breast or early stage cancer of the womb.
Medical conditions
You cannot join this trial if any of these apply. You:
- have had a heart attack or heart surgery in the last 6 months or a significant
heart problem that needs treatment
- are taking certain medications that you can’t have in the trial. Your doctor will know this.
- break down some medicines in the body very slowly. Your doctor will test for this.
- have an
autoimmune condition that needs treatment apart from certain ones. Your doctor will know about this.
- have had treatment that damps down the
immune system . This includes steroids within 2 weeks of starting trial treatments unless it was a low dose.
- have scarring on the lungs that is causing symptoms or could interfere with monitoring side effects that affect the lung.
- have side effects from past treatment that aren’t getting better. You can take part if you have hair loss or white patches on your skin.
- have HIV, an active hepatitis B or hepatitis C infection or another infection that needs treatment to the whole body
- regularly take aspirin, you took it regularly in the past or you take a type of drug called a non steroidal anti inflammatory drug
- have another medical condition or mental health condition that could affect you taking part in the trial or there is another reason the trial team think you won’t be suitable to take part
Other
You cannot join this trial if any of these apply. You:
- are allergic to celecoxib
- are allergic to a type of drug called a sulphonamide
- have had a
live vaccination within 30 days of joining the trial. This is apart from the seasonal flu vaccine or the approved COVID-19 vaccines as these aren’t live.
- are pregnant or breastfeeding
Trial design
This is a phase 2 trial. There are 3 groups and the group you join depends on your cancer type.
The team need:
- 26 people who have triple negative breast cancer
- 31 people who have non small cell lung cancer
- 32 people who have renal cell cancer
Everyone in the trial has treatment for as long as it is working and the side effects aren’t too bad. Your doctor will talk to you about other treatment options if you stop trial treatment.
Triple negative breast cancer
You have atezolizumab and nab-paclitaxel as a drip into a vein.
You have treatment in 4 week periods called . In each cycle you have:
- atezolizumab every 2 weeks
- nab-paclitaxel once a week for 3 weeks and then have a week off
Celecoxib is a capsule. You take it twice a day every day.
Renal cell cancer
You have ipilimumab and nivolumab as a drip into a vein. You have it every 3 weeks. After four treatments of ipilimumab and nivolumab, you then continue to have only nivolumab. You have this every 4 weeks.
Celecoxib is a capsule. You take it twice a day every day.
Non small cell lung cancer
You have pembrolizumab as a drip into a vein. You have it every 3 weeks. This is ongoing.
Celecoxib is a capsule. You take it twice a day every day.
Patient diary
Everyone fills in a diary card. This is to record when you take celecoxib and if you miss any doses.
Samples for research
The researchers might ask to take extra tissue samples () if there isn’t a previous sample that they can use. They also ask to have a piece of cancer tissue if you have a sample taken as part of your routine care. You don’t have to agree to give the extra tissue samples if you don’t want to. It won’t affect you taking part in the rest of the trial.
The team ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
- see how well the treatment is working
- look for small pieces of cancer DNA in the blood (
ctDNA )
- look at immune cells
You also give some urine samples if you have renal cell cancer.
The team will also ask your permission to store some samples for future research. You don’t have to agree to this.
Hospital visits
You see the doctor for a and have tests before you can take part. These include:
- blood tests
- a urine test
- a CT scan
You might also need to have an MRI scan.
You have your standard treatment at the hospital in the outpatient department. During treatment you see the doctor regularly. This is for blood tests and to see how you are.
Trial scans
During treatment you have a CT scan once every 9 weeks. You stop having the trial scans if your cancer gets worse.
Follow up
When you stop treatment you see the trial team one month later. The team then follow you up every 3 months. They may call you to see how you are getting on, or check your medical notes.
Side effects
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
The common side effects of celecoxib include:
- high blood pressure
- heart problems such as heart attacks
- stomach problems including tummy (abdominal) pain
- indigestion
- problems swallowing
- diarrhoea
- being sick
- an allergic reaction or skin rash
sinus infection blocked or runny nose and flu-like symptoms
- infections including urine infections
- weight gain
- swollen ankles, feet or hands
- kidney stones
- an enlarged
prostate - dizziness
- difficulty sleeping
- joint pain
Atezolizumab, pembrolizumab, nivolumab and ipilimumab can affect the These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for. |
We have more information about the following drugs and their side effects:
Location
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Anne Armstrong
Supported by
The Christie NHS Foundation Trust
The Jon Moulton Charity Trust
The Christie Charity
Liverpool Clinical Trials Centre
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040